Skip to main content
U.S. flag

An official website of the United States government

Return to search results
💡 Advanced Search Tip

Search by organization or tag to find related datasets

Results of the Ticlid or Plavix Post-Stents (TOPPS) trial: do they justify the switch from ticlopidine to clopidogrel after coronary stent placement?

Published by National Institutes of Health | U.S. Department of Health & Human Services | Metadata Last Checked: September 06, 2025 | Last Modified: 2025-09-06
In the Ticlid or Plavix Post-Stents (TOPPS) trial, 1016 patients undergoing successful coronary stent placement were randomized to receive aspirin and either ticlopidine or clopidogrel. In this trial, the dosages and regimens of ticlopidine and clopidogrel resembled more closely those used in most catheterization laboratories than did the two previous randomized trials comparing ticlopidine and clopidogrel. The results of the TOPPS trial support the current practice of substituting ticlopidine for clopidogrel in stent patients.

Find Related Datasets

Click any tag below to search for similar datasets

Complete Metadata

data.gov

An official website of the GSA's Technology Transformation Services

Looking for U.S. government information and services?
Visit USA.gov